The point prevalence of systemic inflammation at the data cutoff date (31 July 2023) was 56% among alive patients with at least one CRP measurement in the prior 18 months, and it was greater among the patients with ASCVD and CKD (62%) than in the patients with ASCVD without CKD (52%). Here, CRP is linked to chronic kidney disease.